

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

LOCOREGIONAL + SYSTEMIC

NRG GI012

Atezo/bev, Durva/treme,
Nivo/ipi w/wo SBRT

Coord: B. Nguyen
Accrual: 1/5

FIRST LINE

UCI 22-106

STAT3 + Atezolizumab and Bevacizumab
(Slot request required)
Coord: H. Nguyen
Accrual: 10/15

UCI 22-211

MED1572 (IgG1 mAb) ± Bev
Suspended for additional cohort
Coord: B. Nguyen
Accrual: 4/8

UCI 23-104

Livmoniplimab + Budigalimab
Atezolizumab + Bevacizumab
Tremelimumab + Durvalumab
Suspended until Q2 2026
Coord: S. Duong
Accrual: 3/7

UCI 26-54

PF-08634404 (PD1/VEGF mAb) +
Ipilimumab
Accrual: 0/11
Coord: S. Zamora
Accrual: 0/17

SECOND LINE/THIRD LINE

UCI 16-94

TATE + Nivolumab

Coord: S. Duong
Accrual: 34/48

UCI 24-09

RYZ801 (GPC3 radiotherapeutic)

Accrual: 1/10
Coord: H. Nguyen

UCI 23-215

AZD5851 (GPC3 Autologous CAR-T)
**Central testing for GPC3/GPC3
naïve**
Accrual: 0/5
Suspended until Q3 2026

ETCTN 10703

Sapanisertib (mTOR kinase
inhibitor) + Cabozantinib
B-catenin positivity during Phase 2

Coord: S. Duong
Accrual: 1/3

UCI 25-06

ABBV-324 (GPC3 ADC)

Coord: S. Duong
Accrual: 2/3

UCI 25-218

Visugromab (IgG4 GDF-15)
Nivolumab and Lenvatinib, or
Lenvatinib/double placebo
Accrual: 0/10
DOT approved
Coord: S. Zamora

SYSTEMIC + OPERATIVE

ETCTN 10608
 Gemcitabine + Cisplatin + Durva
 Neo/Adjuvant for **high-risk**
resectable ICC

Coord: H. Nguyen
 Accrual: 2/3

FIRST LINE

UCI 22-211 (GEMINI)
 MED1572 (IgG1 mAb) or
 AZD2936 (TIGIT) ± gemcitabine
 and cisplatin
Slot request

Coord: B. Nguyen
 Accrual: 4/8

UCI 21-10
 TJ033721 (CLDN18 Inhibitor) +
 Gem/Cis/Durva
Slot request
Coord: B. Nguyen
 Accrual: 34/50

UCI 25-204 (Artemide 2)
 Rilvegostomig or Durvalumab
 with Gemcitabine/Cisplatin

Coord: H. Nguyen
 Accrual: 0/10

SECOND LINE+

UCI 25-137
 Nanvuranlat (LAT1 inhibitor) vs.
 Physician choice chemotherapy
 Accrual 0/10
Coord: S. Duong

UCI 23-85
 EpCAM inhibitor
Slot request
Coord: H. Nguyen
 Accrual: 8/18
 Status: suspended for sponsor
 funds

FIRST LINE LA/METASTATIC

SECOND LINE

UCI 23-200

AZD0901 (CLND18 ADC) with
NAL-IRI or Gemcitabine
Slot request

Coord: S. Duong

Accrual: 5/10

UCI 25-216

Relacorilant w/gem/nab-paclitaxel
mPDAC diagnosed w/in 6 weeks
Accrual: 0/10

Distant mets must also be RECIST 1.1
measurable.

Status: Pending MP V7

Coord: H. Nguyen

UCI 24-105

Pitavastatin + Gemcitabine/Nab-paclitaxel
Stable disease after 2 months of treatment w/gem/nab-paclitaxel

Coord: S. Duong

Accrual: 2/18

UCI 21-10

TJ033721 (CLDN18 Inhibitor) +
gemcitabine + nab-paclitaxel
Slot request

Coord: B. Nguyen

Accrual: 34/50

Current status: Enrolling
(8/24/26)

UCI 25-229

3082-CL-0301 (KRAS G12D mPDAC)
w/mFOLFIRINOX or NALIRIFOX
Accrual: 0/8

Status: IRB/CTA/Budget

Coord: B. Nguyen

UCI 25-228

ODM-212 (Hippo pathway)
PDAC – Gemcitabine/Nab-paclitaxel
Accrual: 1/10

Coord: H. Nguyen

UCI 22-51

(PAUSED TO ENROLLMENT)
ASP2138 (CLDN18.2 BiTe) with
FOLFIRINOX

Coord: S. Duong

Accrual: 32/35

UCI 26-21

INCB161734 w/ mFOLFIRINOX or
Gem/Nab-Paclitaxel (DAWN-303)
Accrual: 0/10

Status: IRB/CTA/Budget

Coord: S. Zamora

FIRST LINE SUPPORTIVE CARE

UCI 25-120

Ponsegromab (GD15 blocker) vs.
placebo for cachexia

Accrual: 2/40

Coord: S. Zamora

UCI 26-98

ANO31905 for Injection in Combo
with Chemotherapy - **CLDN 18.2**

Coord: TBD

Accrual: 0/12

Status: New

BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366

M3814 (Peposertib) + radiation
Coord: S. Duong
Accrual: 12/18

ETCTN-10464

Olaparib + Durvalumab + radiation
Coord: S. Duong
Accrual: 1/5

UCI 23-134

Padeliporfin Vascular targeted
photodynamic therapy
Pancreatic head/uncinate

Coord: H. Nguyen
Accrual: 8/15

NRG-GI011

Dose escalated radiation
Coord: B. Nguyen
Accrual: 0/10

UCI 26-100

Perioperative Fostamatinib with
Gemcitabine and Nab-paclitaxel
in Resectable Pancreatic Cancer

Coord: TBD
Accrual: 0/8
Coord: TBD

Open to Accrual

Low Accruing

Pending Activation/Suspended

RECURRENT/EXHAUSTIVE

UCI 24-08

SPEDOX -6 (Protein
encapsulated doxorubicin)
KRAS Mutation

Coord: B. Nguyen
Accrual: 8/67

UCI 24-113

BMS-986482 (Treg inducer)
PI: Dr. Chow
Coord: S. Duong
Accrual: 5/10

**Review Biomarker Based
Solid Tumors Pages 6 and 7**

ETCTN 10522

CA4948 + gemcitabine + nab-
paclitaxel

Coord: B. Nguyen
Accrual: 5/10

SECOND LINE+

ETCTN 10479

Lu-177 + Sunitinib

Well or moderately differentiated PNET
Up to one line of systemic therapy not
including somatostatin
Slot request required

Coord: H. Nguyen
Accrual: 0/3

UCI 25-75

CRN09682 (NDC MMAE)
NET/NEC/other solid tumors with
SST2 expression on PET/CT
Slot request required

Coord: S. Duong
Accrual: 0/15

UCI 24-138

Various Neuroendocrine including
Gastroenteropancreatic NEN with DLL3
expression on IHC
Slot request required

PI: Dr. Park
Coord: S. Duong
Accrual: 2/5

Mutation based studies allowing Pancreatic, liver, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51
ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ
Coord: TBD
Accrual: 32/35
PI: Dr. Dayyani

MTAP

UCI 24-197
TNG456 (PRMT5 inhibitor)

MTAP NGS/IHC **local** testing
Accrual: 1/5
PI: Dr. Park
Coord: TBD

ALK

UCI 21-241
NVL- 655 (ALK inhibitor)
Accrual: 20/25
PI: Dr. Nagasaka
Coord: TBD

SMARCA2

UCI 25-194
Drug: PLX-61639 (SMARCA2 degrader)

Inclusive of all solid tumors with SMARCA4 mutations
Accrual: 0/5
PI: Dr. Villaflor
Coord: TBD

HER2

ETCTN-10495
(+ Neratinib)
Accrual: 2/7
PI: Dr. Dayyani
Status: Suspended
Coord: TBD

KRAS

UCI 25-163
Drug:BBO-11818

Inclusive of all solid tumors with KRAS G12C, G12D, G12V
Emphasis on NSCLC, CRC, and PDAC
Accrual: 0/5
PI: Dr. Arter
Status: IRB initial approval
Coord: TBD

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Accrual: 11/12

Coord: B. Nguyen

Status: Suspended for analysis

UCI 24-142

VET3-TGI (IL-12 and TGF-B inhibiting vaccine) ±

Pembrolizumab

Intra-tumoral or IV

Accrual: 2/4

PI: Dr. Uchio

Coord: TBD

Slot request required

UCI 25-16

ODM-212 (Hippo pathway)

Reach out to coordinator for selected tumor types

Accrual: 8/10

Coord: TBD

PI: Dr. Dayyani

Slot request required

UCI 25-228

ODM-212 (Hippo pathway)

Lung - Sotorasib

Mesothelioma –

Ipililumab/Nivolumab

PDAC – Gemcitabine/Nab-

paclitaxel

Accrual: 1/10

Coord: H. Nguyen

ETCTN 10579

Drug: ZEN-3694 (BET Inhibitor) + capecitabine

Inclusive of all solid tumors in dose escalation

Accrual: 2/4

PI: Dr. Lee

Slot request Required

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: TBD
Accrual: 17/19

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Coord: TBD
Accrual: 1/20

UCI 22-55

Blood and biomarker
collection for early detection
and diagnosis of DNA
Deficient Hereditary Cancers

Investigators: Dr. Jennifer
Valerin and Dr. Nicholas
Pannunzio
Accrual: 16/50
Coord: TBD

BEHAVIORAL

UCI 25-177

Refinement and usability of e-
support for pancreatic cancer
patients

Coord: TBD
Investigator: Dr. Jacqueline Kim